Immutep Limited (NASDAQ:IMMP - Get Free Report) shares passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.18 and traded as low as $1.80. Immutep shares last traded at $1.84, with a volume of 70,057 shares traded.
Immutep Trading Up 0.5 %
The company has a debt-to-equity ratio of 0.01, a current ratio of 18.25 and a quick ratio of 18.25. The company's 50-day moving average is $2.18 and its two-hundred day moving average is $2.35.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in Immutep during the 2nd quarter valued at $26,000. BNP Paribas Financial Markets lifted its holdings in Immutep by 15.4% during the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company's stock worth $82,000 after acquiring an additional 4,700 shares during the period. XY Capital Ltd bought a new position in Immutep in the 2nd quarter valued at $105,000. Virtu Financial LLC raised its stake in shares of Immutep by 269.4% during the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company's stock worth $105,000 after purchasing an additional 32,864 shares during the period. Finally, Oracle Investment Management Inc. boosted its holdings in shares of Immutep by 9.4% in the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company's stock worth $1,316,000 after buying an additional 48,449 shares during the last quarter. Hedge funds and other institutional investors own 2.32% of the company's stock.
Immutep Company Profile
(
Get Free Report)
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Featured Articles
Before you consider Immutep, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.
While Immutep currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
